Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!
A complete application consists of:
All documents must be in English or include an official English translation.
If you have questions, send an email to ORISE.FDA.CFSAN@orau.org. Please include the reference code for this opportunity in your email.
*Applications will be reviewed on a rolling-basis and this opportunity will remain open until filled.
A research opportunity is currently available at the U.S. Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition (CFSAN), located in College Park, Maryland.
The FDA received funding to build public health capacity, in the form of SARS CoV-2 (SC2) surveillance, by expanding the GenomeTrakr network of state and local laboratories that conduct genomic pathogen surveillance for rapid investigation of illness and outbreaks. This includes a more integrated infrastructure and funding for public health sequencing of human, animal and plant pathogens through a distributed lab infrastructure including public and private labs, all feeding the information into publicly-accessible, open databases.
The selected fellow will assist in the development of metagenomic and metatranscriptomic sequencing workflows that can be implemented and integrated into the framework of wastewater surveillance testing methods for SC2. Specifically, nucleic acid extraction protocols to target SC2 will be optimized to reduce viral genome degradation, mitigate common inhibitors in wastewater samples, enhance sequence quality, and ease of use and automation. Sequencing library preparation will follow established protocols with optimization for the sample matrix and will include several process controls, such as matrix recovery control, human fecal normalization, quantitative measurement controls, inhibition assessment, and negative controls. Library preparation methods will be assessed based on benchmark or previously characterized samples to determine optimal manufacturer protocols, including modifications, and multiplexing strategies.
The fellow will be involved in the following research activities:
Under the guidance of a mentor, the participant will have the following learning opportunities:
Anticipated Appointment Start Date: September 1, 2022; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the College Park, Maryland area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
The qualified candidate should be currently pursuing a bachelor's or master's degree in one of the relevant fields (e.g. Microbiology, Biology, Genetics, Genomics).
I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)